Clinical trials: Melanoma of Skin
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma (Skin)
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
RATIONALE: Cytotoxic T lymphocytes (CTL) are cells of the immune system that can fight infections and cancer. These CTL can be manipulated in the laboratory so that they can target an individual's cancer.
- Trial name
- NCT00512889
- Testing
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Circulating tumor cells (CTC) are the subject of increasing interest in clinical oncology as a prognostic factor and predictor of therapeutic response.
- Trial name
- NCT01573494
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Melanoma Stage Iv, Melanoma Stage Iii
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Melanoma
- Trial name
- CHARLI (NCT03161756)
- Testing
- Denosumab, Nivolumab, Ipilimumab
- Where
- 10 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year.
- Trial name
- NCT04844528
- Testing
- Nicotinamide
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of Utah
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Melanoma
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition.
- Trial name
- NCT02557321
- Testing
- PV-10, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Skin Cancer
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center.
- Trial name
- NCT07177638
- Testing
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Melanoma (Skin)
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00054535
- Testing
- aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients
The effectiveness of propranolol in infantile hemangiomas, the apparent better response to propranolol in breast cancer and the use of propranolol in a proportion of patients who did not develop melanoma recurrence suggested to…
- Trial name
- NCT02962947
- Testing
- Propranolol
- Volunteers
- 546 people
- Sponsor
- Azienda Sanitaria di Firenze
Melanoma, Tumor Vaccines
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma
The primary objective of this study is to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a dendritic cell-based cancer vaccine, in patients with melanoma.
- Conditions
- Melanoma, Tumor Vaccines, Effects of Immunotherapy
- Trial name
- GeniusVac-Mel4 (NCT01863108)
- Testing
- GeniusVac-Mel4
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Grenoble
Metastatic Melanoma, Cutaneous Melanoma
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma.
- Trial name
- NCT00679289
- Testing
- HDI, KW2871
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma, Neoplasm
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
- Trial name
- NCT00062491
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Malignant Melanoma
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
This is the phase II, single-arm, single-center study assessing the efficacy of weekly docetaxel plus carboplatin in second-line treatment of malignant melanoma (unresectable or metastatic) who has failed dacarbazine or…
- Trial name
- NCT02223884
- Testing
- docetaxel 35mg/m2, Carboplatin AUC3
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Malignant Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
The purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line…
- Trial name
- NCT04889118
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 11 sites in China
- Volunteers
- 131 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Genetic Polymorphism
Multicentric Cohort of Melanoma Patients in Ile de France Area
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe.
- Trial name
- Melan-Cohort (NCT00839410)
- Where
- France
- Volunteers
- 1,255 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
- Trial name
- NCT01864538
- Testing
- TH-302
- Where
- 7 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- ImmunoGenesis
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.